Kidney TransplantationPhase 3NCT00481819
A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation
A Phase 3 study testing FK506MR, Prograf and Mycophenolate Mofetil in people with Kidney Transplantation, run by Astellas Pharma Inc at 9 sites in China.
Trial summary
The patients about to undergo kidney transplantation will be randomized to one of the following two group: Group FK506MR: FK506MR/MMF/steroid; Group Prograf® : Prograf® /MMF/steroid. The treatment period is 3 months( 12 weeks) Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Kidney Transplantation
- What is being tested?
- FK506MR, Prograf and Mycophenolate Mofetil
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- 9 sitesChina
- Study dates
- Jul 2007to Mar 2009
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent with the date of the patient must be obtained.
- Patient between 18-70 years of age receiving the primary kidney.
- Female patients must have a negative pregnancy test prior to the enrolment.
- Female patients of child bearing potential must agree to practice effective birth control during the study.
Who cannot join
- Kidney re-transplantation patients or received an organ transplantation other than a kidney.
- PRA>10% in the previous 6 months.
- Patient who need antibody induction therapy.
- Patient with significant liver disease, defined as having continuously elevated >2 times of SGPT and/or SGOT and/or total bilirubin levels during the past 28 days.
- Patient with severe infection requiring treatment, and/or severe diarrhea, vomiting, active upper gastrointestinal tract malabsorption or active peptic ulcer.
- Patient has any history of severe cardiovascular, respiratory disease; or history of malignancy.
- Patient is HIV or HBsAg positive.
- Patient is allergic to Prograf or macrolide antibiotics.
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
China9 sites
3 Sites
Beijing, Beijing Municipality
Study site
Changsha, Hunan
Study site
Chongqing, Sichuan
Study site
Fuzhou, Fujian
2 Sites
Guangzhou, Guangdong
Study site
Hangzhou, Zhejiang
2 Sites
Shanghai, Shanghai Municipality
Study site
Shenyang, Liaoning
Study site
Wuhan, Hubei
About this study
Official title: A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study.
The patients about to undergo kidney transplantation will be randomized to one of the following two group:
Group FK506MR: FK506MR/MMF/steroid; Group Prograf® : Prograf® /MMF/steroid. The treatment period is 3 months( 12 weeks)
- Conditions
- Kidney Transplantation
- Being tested
- FK506MR, Prograf, Mycophenolate Mofetil, Methylprednisolone, Prednisolone
- Keywords
- Kidney Transplantation, Tacrolimus, Methylprednisolone, Prednisolone, Mycophenolate Mofetil
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FK506MRDrug
Also called Advagraf, Tacrolimus modified-release, MR4
oral
PrografDrug
Also called tacrolimus, FK506
oral
Also called MMF
oral
oral
PrednisoloneDrug
oral
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | In combination with MMF and steroids Receives: Drug: FK506MR; Drug: Mycophenolate Mofetil; Drug: Methylprednisolone; Drug: Prednisolone |
| 2 | Active comparator | In combination with MMF and steroids Receives: Drug: Prograf; Drug: Mycophenolate Mofetil; Drug: Methylprednisolone; Drug: Prednisolone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Event rate of patients with acute rejections
Measured: 12 weeks
Secondary outcomes (3)
Incidence of and time to acute rejections
Measured: 12 Weeks
Overall frequency of acute rejections
Measured: 12 Weeks
Rate of patient and graft survival following transplantation
Measured: 12 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2007 (estimated)
- Study startJul 2007
- Primary completionMar 2009
- Study completionMar 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 240 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Prof. Ao Jianhua, Principal investigator, Department of Urologic Surgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00481819
- Sponsor's protocol ID
- MR4KTxCN01
- Status last verified
- Feb 2016
- First submitted
- 31 May 2007
- Last updated
- 24 Feb 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study.
- ClinicalTrials.gov ID
- NCT00481819
- Acronym / sponsor ID
- MR4KTxCN01
- Conditions
- Kidney Transplantation
- Keywords
- Kidney Transplantation, Tacrolimus, Methylprednisolone, Prednisolone, Mycophenolate Mofetil
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 240 participants (actual)
- Lead sponsor
- Astellas Pharma IncIndustry (pharma, biotech, devices)
- Study start
- Jul 2007
- Primary completion
- Mar 2009 (actual)
- Study completion
- Mar 2009 (actual)
- First posted
- 4 Jun 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The patients about to undergo kidney transplantation will be randomized to one of the following two group:
Group FK506MR: FK506MR/MMF/steroid; Group Prograf® : Prograf® /MMF/steroid. The treatment period is 3 months( 12 weeks)
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: FK506MR, Drug: Mycophenolate Mofetil, Drug: Methylprednisolone, Drug: PrednisoloneIn combination with MMF and steroids |
| 2 | Active comparator | Drug: Prograf, Drug: Mycophenolate Mofetil, Drug: Methylprednisolone, Drug: PrednisoloneIn combination with MMF and steroids |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Written informed consent with the date of the patient must be obtained.
- Patient between 18-70 years of age receiving the primary kidney.
- Female patients must have a negative pregnancy test prior to the enrolment.
- Female patients of child bearing potential must agree to practice effective birth control during the study.
Key exclusion criteria (8 listed)
- Kidney re-transplantation patients or received an organ transplantation other than a kidney.
- PRA>10% in the previous 6 months.
- Patient who need antibody induction therapy.
- Patient with significant liver disease, defined as having continuously elevated >2 times of SGPT and/or SGOT and/or total bilirubin levels during the past 28 days.
- Patient with severe infection requiring treatment, and/or severe diarrhea, vomiting, active upper gastrointestinal tract malabsorption or active peptic ulcer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FK506MRAlso: Advagraf, Tacrolimus modified-release, MR4oral | Drug | 1 |
| PrografAlso: tacrolimus, FK506oral | Drug | 2 |
| Mycophenolate MofetilAlso: MMForal | Drug | 1, 2 |
| Methylprednisoloneoral | Drug | 1, 2 |
| Prednisoloneoral | Drug | 1, 2 |
Primary outcome
Event rate of patients with acute rejections
Time frame: 12 weeks
3 secondary outcomes
Incidence of and time to acute rejections
Time frame: 12 Weeks
Overall frequency of acute rejections
Time frame: 12 Weeks
Rate of patient and graft survival following transplantation
Time frame: 12 Weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2016.
- Individual participant dataSharing planned: Undecided
Related trials for Kidney Transplantation
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruitingEarly Phase 1
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Kidney Transplant Recipient
Recruiting
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Pediatric Kidney Disease, Transplant;Failure,Kidney
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Prof. Ao Jianhua principal investigator
Department of Urologic Surgery
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing FK506MR, Prograf and Mycophenolate Mofetil in people with Kidney Transplantation, run by Astellas Pharma Inc at 9 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Event rate of patients with acute rejections (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2016.